Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption
作者:Jeffrey A. Pfefferkorn、Scott D. Larsen、Chad Van Huis、Roderick Sorenson、Tom Barton、Thomas Winters、Bruce Auerbach、Chenyan Wu、Thaddeus J. Wolfram、Hongliang Cai、Kathleen Welch、Nadia Esmaiel、JoAnn Davis、Richard Bousley、Karl Olsen、Sandra Bak Mueller、Thomas Mertz
DOI:10.1016/j.bmcl.2007.11.083
日期:2008.1
Cholesterol absorption inhibition (CAI) represents an important treatment option for hypercholesterolemia. Herein, we report the design and evaluation of a series of substituted oxazolidinones as ligands for the Niemann Pick C1 Like 1 (NPC1L1) protein, a key mediator of cholesterol transport. Novel analogs were initially evaluated in a brush border membrane NPC1L1 binding assay; subsequently, promising compounds were evaluated in vivo for acute inhibition of cholesterol absorption. These studies identified analogs with low micromolar NPC1L1 binding affinity and acute in vivo efficacy of >50% absorption inhibition at 3 mg/kg. (c) 2007 Elsevier Ltd. All rights reserved.
[EN] OXAZOLIDINONES AS CHOLESTEROL ABSORPTION INHIBITORS<br/>[FR] OXAZOLIDINONES COMME INHIBITEURS D'ABSORPTION DE CHOLESTÉROL
申请人:PFIZER PROD INC
公开号:WO2008104875A1
公开(公告)日:2008-09-04
[EN] Novel oxazolidinones and pharmaceutical compositions are described, as are methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholeserolemia, and atherosclerosis. [FR] L'invention porte sur de nouvelles oxazolidinones et compositions pharmaceutiques, ainsi que sur des procédés d'utilisation de tels composés et compositions pour traiter des sujets, y compris les êtres humains, souffrant d'hyperlipidémie, d'hypercholestérolémie et d'athérosclérose.